Tanvex BioPharma Inc
TWSE:6541

Watchlist Manager
Tanvex BioPharma Inc Logo
Tanvex BioPharma Inc
TWSE:6541
Watchlist
Price: 68.1 TWD -2.44% Market Closed
Market Cap: 11.2B TWD
Have any thoughts about
Tanvex BioPharma Inc?
Write Note

Tanvex BioPharma Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Tanvex BioPharma Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Tanvex BioPharma Inc
TWSE:6541
Depreciation & Amortization
-NT$1.4m
CAGR 3-Years
25%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Beigene Ltd
SSE:688235
Depreciation & Amortization
-ÂĄ363.1m
CAGR 3-Years
-1%
CAGR 5-Years
-65%
CAGR 10-Years
N/A
Polaris Group
TWSE:6550
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tanvex BioPharma Inc
Glance View

Market Cap
11.2B TWD
Industry
Biotechnology

Tanvex BioPharma, Inc. operates as clinical stage company, which engages in the research and development, production, and sale of pharmaceutical products. The firm is also engaged in areas of strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing and warehousing, sales and distribution. The Company’s product pipeline includes Neupogen (TX-01), TX-05, TX-04, TX-16, TX-52, and others. The firm offers a vertically integrated manufacturing platform for biopharmaceuticals. By controlling the entire process from research and development (R&D) and cell-line development. The firm is developing and delivering biologic and biosimilar drugs to the people.

Intrinsic Value
1.61 TWD
Overvaluation 98%
Intrinsic Value
Price

See Also

What is Tanvex BioPharma Inc's Depreciation & Amortization?
Depreciation & Amortization
-1.4m TWD

Based on the financial report for Jun 30, 2024, Tanvex BioPharma Inc's Depreciation & Amortization amounts to -1.4m TWD.

What is Tanvex BioPharma Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
29%

Over the last year, the Depreciation & Amortization growth was -17%. The average annual Depreciation & Amortization growth rates for Tanvex BioPharma Inc have been 25% over the past three years , 29% over the past five years .

Back to Top